How To Cut Out The Clutter When Considering A Relapsing MS Treatment Sponsored Post

How To Cut Out The Clutter When Considering  A Relapsing MS Treatment <span>Sponsored Post</span>
0
(0)

With 18+ disease-modifying treatments (DMTs) on the market, it can be difficult to choose which is for your relapsing multiple sclerosis. Treatment comes in three forms: injection, infusion and pill.1 The uncertainty of relapsing MS adds yet another factor in the decision-making process. Luckily, you don’t have to look alone. Whether you are starting your first treatment or changing your current treatment, you and your healthcare provider (HCP) will make the choice as a team.2 It is possible to sort through the DMT landscape with confidence, even if you’ve been here before and thought you’d seen it all.

Start by asking yourself these questions before your next visit with your HCP.

Keep long-term goals in focus. In addition to examining things like reducing relapses and slowing disability progression, look at the long-term effectiveness for any treatment you’re considering. Since relapsing MS is a lifelong journey, it is important to be confident that your treatment is effective when you begin, as well as over time.2

Be sure to also investigate possible side effects. Think about what you are willing to tolerate. Each medication is different, and it will have its own set of possible side effects. And just because you may have had a problem with one medication that doesn’t mean you’ll have the same problem with another.4

Remember to ask your doctor about safety history. It’s worth exploring if any treatment you’re thinking about has been studied for safety over time.2

Be open with your HCP. Share your concerns, experiences, and even your wish list for your future. Your input helps to create the full picture. That way when you both choose a relapsing MS treatment, you’re getting the one that best suits your needs overall — and over time.2


AUBAGIO is proven to treat relapsing MS in 3 key ways:5

  • AUBAGIO 14 mg was effective against placebo (pills with no medicine) in: reducing relapses, decreasing number of new lesions, and slowing disability progression.*

You can take AUBAGIO any time of day, with or without food. Ask your healthcare provider if AUBAGIO may help you manage your relapsing MS. Your healthcare provider will run certain tests before you start treatment. Once on AUBAGIO, your healthcare provider will monitor your liver enzyme levels monthly for the first 6 months and conduct periodic blood pressure checks.5

AUBAGIO’S 15+ YEAR HISTORY INCLUDES CLINICAL TRIAL DATA AND REAL-WORLD EXPERIENCE5

When choosing a treatment with your doctor, ask about the well-established history of AUBAGIO.

Visit AUBAGIO.com and get all the facts so you can make informed treatment decisions with your HCP.

*Clinical Trial 1 (TEMSO) included 1088 people over 2 years. Clinical Trial 2 (TOWER) included 1165 people over 2 years. AUBAGIO 14 mg and 7 mg achieved a significant relative risk reduction in relapse rate in TEMSO (31%, 31%) and TOWER (36%, 22%) versus placebo. AUBAGIO 14 mg and 7 mg significantly decreased the number of new lesions in TEMSO (80%, 57%) versus placebo. 80% of patients in TEMSO and 84% of patients in TOWER remained free from disability progression with AUBAGIO 14 mg versus placebo (73% and 80%, respectively) over 108 weeks. AUBAGIO 7 mg did not achieve statistical significance in either trial. The most common side effects include: headache (16%, 18%, 15%), diarrhea (14%, 13%, 8%), nausea (11%, 8%, 7%), hair thinning or loss (13%, 10%, 5%), and abnormal liver test results (15%, 13%, 9%) for 14 mg, 7 mg, and placebo, respectively.5

INDICATION

AUBAGIO® (teriflunomide) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

IMPORTANT SAFETY INFORMATION

DO NOT TAKE AUBAGIO IF YOU:

  • Have severe liver problems. AUBAGIO may cause serious liver problems, which can be life-threatening. Your risk may be higher if you take other medicines that affect your liver. Your healthcare provider should do blood tests to check your liver within 6 months before you start AUBAGIO and monthly for 6 months after starting AUBAGIO. Tell your healthcare provider right away if you develop any of these symptoms of liver problems: nausea, vomiting, stomach pain, loss of appetite, tiredness, yellowing of your skin or whites of your eyes, or dark urine.
  • Are pregnant. AUBAGIO may harm an unborn baby. You should have a pregnancy test before starting AUBAGIO. After stopping AUBAGIO, continue to use effective birth control until you have made sure your blood levels of AUBAGIO are lowered. If you become pregnant while taking AUBAGIO or within 2 years after stopping, tell your healthcare provider right away and enroll in the AUBAGIO Pregnancy Registry at 1-800-745-4447, option 2.
  • Are of childbearing potential and not using effective birth control.

It is not known if AUBAGIO passes into breast milk. Your healthcare provider can help you decide if you should take AUBAGIO or breastfeed — you should not do both at the same time.

If you are a man whose partner plans to become pregnant, you should stop taking AUBAGIO and talk with your healthcare provider about reducing the levels of AUBAGIO in your blood. If your partner does not plan to become pregnant, use effective birth control while taking AUBAGIO.

  • Have had an allergic reaction to AUBAGIO or a medicine called leflunomide.
  • Take a medicine called leflunomide for rheumatoid arthritis.

AUBAGIO may stay in your blood for up to 2 years after you stop taking it. Your healthcare provider can prescribe a medicine that can remove AUBAGIO from your blood quickly.

Before taking AUBAGIO, talk with your healthcare provider if you have: liver or kidney problems; a fever or infection, or if you are unable to fight infections; numbness or tingling in your hands or feet that is different from your MS symptoms; diabetes; serious skin problems when taking other medicines; breathing problems; or high blood pressure. Your healthcare provider will check your blood cell count and TB test before you start AUBAGIO. Talk with your healthcare provider if you take or are planning to take other medicines (especially medicines for treating cancer or controlling your immune system), vitamins or herbal supplements.

AUBAGIO may cause serious side effects, including: reduced white blood cell count — this may cause you to have more infections; numbness or tingling in your hands or feet that is different from your MS symptoms; allergic reactions, including serious skin problems; breathing problems (new or worsening); and high blood pressure. Patients with low white blood cell count should not receive certain vaccinations during AUBAGIO treatment and 6 months after.

Tell your doctor if you have any side effect that bothers you or does not go away.

The most common side effects when taking AUBAGIO include: headache; diarrhea; nausea; hair thinning or loss; and abnormal liver test results. These are not all the side effects of AUBAGIO. Tell your healthcare provider about any side effect that bothers you.

Consult your healthcare provider if you have questions about your health or any medications you may be taking, including AUBAGIO.

Please click here for full Prescribing Information, including boxed WARNING and Medication Guide.

Advertisement

1. National Multiple Sclerosis Society. Medications. https://www.nationalmssociety.org/Treating-MS/Medications. Accessed May 21, 2020. 2. Pardo G, Jones DE. The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. J Neurol. 2017;264(12):2351-2374. doi:10.1007/s00415-017-8594-9. 3. Giovannoni G, Rhoades RW. Individualizing treatment goals and interventions for people with MS. Curr Opin Neurol. 2012;25(suppl 1):S20‐S27. 4. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):777‐788. doi:10.1212/WNL.0000000000005347. 5. AUBAGIO (teriflunomide) [package insert]. Cambridge, MA: Genzyme Corporation.

MAT-US-2007991-v1.0-09/2020
Last Updated: 09/20

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?